Main Article Content
people living with HIV, AIDS, vaccination, guidelines
Background and aim: : In the world 37,9 billions live with Human Immunodeficiency Virus and, despite the availability of retroviral therapy, they have an higher risk to acquire other infectious diseases and to develop severe complications. According to several guidelines their immunization is crucial but only some center have developed a specific scheduled pathway and vaccination coverage is very low. Aim of this study is: a)incentivize the active and free of charge offer of vaccines and increase of immunization coverage; b) application and implementation of a shared clinical pathway avoiding reluctance, embarrassment or shame by patients for their condition; d) instauration of an empathic relationship between doctor and patient; e) evaluation of side effects.
Methods: A prospective study was conducted from October 2019 to February 2020 at the University Hospital G. Martino of Messina. Inclusion criteria were: age over 18; absence of other diseases; absence of immunization against HBV or HAV; CD4 count for live attenuated viral vaccines of 350/uL and for other vaccine 200/uL. A specific scheduled pathway was adopted for every patient. Statistical analysis was performed with Excel software.
Results: 86 patients were enrolled (74.4% were males, 79.1% were Italian; mean age=4013.3 SD). An increase in administration was observed between 2018 and 2019 (+164.3% for flu and for other vaccines +370%). The higher increase was observed for HPV one. No-one received DTpa, MMRV or Zoster vaccine.
Conclusions: The undertook clinical pathway showed the relevance of specific management of these patients and the need to increase the vaccination offer.
2. UNAIDS. Joint United Nations. Programme on HIV/AIDS. Global AIDS update 2019 — Communities at the centreDefending rights, breaking barriers, reaching people with HIV services. 10 December 2019.
3. Jilich D, Malý M, Fleischhans L, Kulířová V, Machala L. Cross-sectional study on vaccination coverage in newly diagnosed HIV-infected persons in the Czech Republic. Cent Eur J Public Health. 2019 Sep;27(3):217-222. doi: 10.21101/cejph.a5830.
4. Società Italiana di Malattie Infettive e Tropicali. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 - anno 2017.
5. Piano Nazionale della Prevenzione Vaccinale 2017-2019. Ministero della Salute. Direzione Generale della Prevenzione Sanitaria
6. Center of Disease Control. Vaccinations for Adults with HIV Infection. CDC, Atlanta.
7. World Health Organization. Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region, 20 March 2020 (produced by WHO/Europe).
8. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective. AIDS Behav. 2020 Aug;24(8):2244-2249. doi: 10.1007/s10461-020-02871-9.
9. Sticchi L, Di Biagio A, Giacomini M et al. (2017). La vaccinazione nel paziente con infezione da HIV: attuali raccomandazioni e strategie multidisciplinari per il raggiungimento dei soggetti suscettibili. L’esperienza della Liguria.JHA - Journal of HIV and Ageing. 10.19198/JHA31436.
10. D’Andrea F, Ceccarelli M, Venanzi Rullo E, et al. Vaccines against HPV in people living with HIV: a review. WCRJ 2019; 6: e1348. DOI: 10.32113/wcrj_20197_1348
11. Kagina, B.M., Wiysonge, C.S., Lesosky, M. et al. Safety of licensed vaccines in HIV-infected persons: a systematic review protocol. Syst Rev 3, 101 (2014). https://doi.org/10.1186/2046-4053-3-101
12. Liguria, Valour F, Cotte L, et al. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine. 2014 Jul 31;32(35):4558-4564. doi: 10.1016/j.vaccine.2014.06.015.
13. Pinto Neto LFDS, Vieira JV, Ronchi NR. Vaccination coverage in a cohort of HIV-infected patients receiving care at an AIDS outpatient clinic in Espírito Santo, Brazil. The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2017 Sep - Oct;21(5):515-519. DOI: 10.1016/j.bjid.2017.03.021.
14. Gagneux-Brunon A, Fresard A, Lucht F, Botelho-Nevers E. Vaccine coverage in PLWH: disparities and potential impact of vaccine hesitancy. Hum Vaccin Immunother. 2019;15(2):305-306. doi: 10.1080/21645515.2018.1534517.
15. Valour F, Cotte L, Voirin N, et al. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine. 2014 Jul 31;32(35):4558-4564. doi: 10.1016/j.vaccine.2014.06.015. Epub 2014 Jun 18. PMID: 24951870.
16. Tsachouridou O, Georgiou A, Naoum S et al. Factors associated with poor adherence to vaccination against hepatitis viruses, streptococcus pneumoniae and seasonal influenza in HIV-infected adults. Hum Vaccin Immunother. 2019;15(2):295-304. doi: 10.1080/21645515.2018.1509644.
17. Facciolà A, Visalli G, Laganà P et al. The new era of vaccines: the "nanovaccinology". Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):7163-7182. doi: 10.26355/eurrev_201908_18763.
18. Larson HJ, de Figueiredo A, Xiahong Z et al. The State of vaccine confidence 2016: global insights through a 67-Country Survey. EBioMedicine. 2016 Oct;12:295–301. doi:10.1016/j. ebiom.2016.08.042.
19. Sticchi L, Bruzzone B, Caligiuri P et al. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccin Immunother. 2015;11(1):263-9. doi: 10.4161/hv.36162.
20. Pandolfi E, Carloni E, Marino MG et al. Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine 2012; 30:5172- 8; PMID:21414380.
21. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2020 – 2019 data. Copenhagen: WHO Regional Office for Europe; 2020.
22. Stannah J, Silhol R, Elmes J et al. Increases in HIV Incidence Following Receptive Anal Intercourse Among Women: A Systematic Review and Meta-analysis. AIDS Behav. 2020 Mar;24(3):667-681. doi: 10.1007/s10461-019-02651-0.
23. European Centre for Disease Prevention and Control. Hepatitis A. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC; 2019
24. Sistema epidemiologico integrato delle epatiti virali acute (Seieva). Available on https://www.epicentro.iss.it/epatite/Bollettino-Seieva. Last access on 02 March 2021.
25. Brown JL, Diclemente RJ. Secondary HIV prevention: novel intervention approaches to impact populations most at risk. Curr HIV/AIDS Rep. 2011 Dec;8(4):269-76. doi: 10.1007/s11904-011-0092-6.
26. Legge 27 maggio 1991, n. 165. Obbligatorietà della vaccinazione contro l'epatite virale B. GU Serie Generale n.127 del 01-06-1991)
27. Agenzia Italiana del Farmaco. Determinazione 28 febbraio 2007. Regime di rimborsabilita' e prezzo di vendita della specialita' medicinale «Gardasil» (vaccino papillomavirus umano), autorizzata con procedura centralizzata europea dalla Commissione europea. (Determinazione/C n. 129/2007).
28. Ministero della Salute. DIREZIONE GENERALE DELLA PREVENZIONE SANITARIA Ufficio 5 - Prevenzione delle Malattie Trasmissibili e profilassi internazionale. Coperture vaccinali al 31.12.2018 per HPV.
29. Gazzetta Ufficiale della Regione Siciliana. Decreto Assesoriale n°1965 del 10 Ottobre 2017,
30. Gazzetta Ufficiale della Regione Siciliana. Decreto Assesoriale _38_12_01_2015
31. Gazzetta Ufficiale della Regione Siciliana. Decreto Assesoriale 0820 2012
32. Personal data not published
33. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS Patient Care STDS 2014; 28: 397-410.
34. Adverse Event HIV/AIDS and immunosuppression – WHO. Available on http://extranet.who.int/ivb_policies/reports/hiv_aids_and_immunosuppression.pdf.
Last access on 2 March 2021.
35. European Medicine Agency. The Committee for Medicinal Products for Human Use (CHMP)
36. Erdmann NB, Prentice HA, Bansal A, Wiener HW, Burkholder G, Shrestha S, Tang J. Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy. Front Public Health. 2018 Mar 12;6:70. doi: 10.3389/fpubh.2018.00070. PMID: 29594092; PMCID: PMC5857573.
37. Shingrix, INN Herpes zoster vaccine (recombinant, adjuvanted). Summary of product characteristics. Availble on: https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_it.pdf . Last access on 2 martch 2021.
38. Oliver S, Gargano J, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep 2020;69:1922-1924. DOI: http://dx.doi.org/10.15585/mmwr.mm6950e2
39. Oliver S, Gargano J, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. MMWR Morb Mortal Wkly Rep 2021;69:1653-1656. DOI: http://dx.doi.org/10.15585/mmwr.mm695152e1.
40. Ferrera G, Squeri R, Genovese C. The evolution of vaccines for early childhood: the MMRV. Ann Ig. 2018 Jul-Aug;30(4 Supple 1):33-37. doi: 10.7416/ai.2018.2232. PMID: 30062378.
41. Squeri R, La Fauci V, Picerno IAM, et al. Evaluation of Vaccination Coverages in the Health Care Workers of a University Hospital in Southern Italy. Annali di Igiene : Medicina Preventiva e di Comunita. 2019 Mar-Apr;31(2 Supple 1):13-24. DOI: 10.7416/ai.2019.2273.
42. Squeri R, Di Pietro A, La Fauci V, Genovese C. Healthcare workers' vaccination at European and Italian level: a narrative review. Acta Biomed. 2019 Sep 13;90(9-S):45-53. doi: 10.23750/abm.v90i9-S.8703.
43. Costantino C, Ledda C, Squeri R, Restivo V, Casuccio A, Rapisarda V, Graziano G, Alba D, Cimino L, Conforto A, Costa GB, D'Amato S, Mazzitelli F, Vitale F, Genovese C. Attitudes and Perception of Healthcare Workers Concerning Influenza Vaccination during the 2019/2020 Season: A Survey of Sicilian University Hospitals. Vaccines (Basel). 2020 Nov 16;8(4):686. doi: 10.3390/vaccines8040686.
44. Genovese, C.; La Fauci, V.; Costa, G.B.; Buda, A.; Nucera, S.; Antonuccio, G.M.; Alessi, V.; Carnuccio, S.; Cristiano, P.; Laudani, N.; et al. A potential outbreak of measles and chickenpox among healthcare workers in a university hospital. EuroMediterranean Biomed. J. 2019, 14, 45–48. [
45. Costantino C, Ledda C, Genovese C, Contrino E, Vitale E, Maida CM, Squeri R, Vitale F, Rapisarda V. Immunization Status against Measles of Health-Care Workers Operating at Three Sicilian University Hospitals: An Observational Study. Vaccines. 2019; 7(4):175. https://doi.org/10.3390/vaccines7040175
46. World Health Organization. Regional Office for Europe. (2020). Strategic considerations in preparing for deployment of COVID-19 vaccine and vaccination in the WHO European Region, 9 October 2020. World Health Organization. Regional Office for Europe. https://apps.who.int/iris/handle/10665/335940. License: CC BY-NC-SA 3.0 IGO